News about Global Pharma

CardioSight Appoints Niv Ad, M.D. as its New Chief Medical Officer

CardioSight, Inc., developer of a revolutionary intravascular visualization and interventional platform, announces the appointment of Niv Ad, M.D., as Chief Medical Officer.

Global Pharma | 01/01/2025 | By Manvi |  115

Innocan Pharma Raises CAD 635,444.60 via Private Placement

Innocan Pharma Corporation has successfully closed a non-brokered private placement, raising CAD 635,444.60. The proceeds are earmarked for advancing its proprietary CBD-loaded liposome technology and general corporate purposes.

Global Pharma | 01/01/2025 | By Manvi |  131

Brii Biosciences Acquires IP Rights for BRII-179 from VBI Vaccines for USD 18 Million

Brii Biosciences Ltd. has acquired the intellectual property and assets of BRII-179 from VBI Vaccines, Inc. and its creditors for USD 18 million, securing full ownership and uninterrupted clinical supply for advancing late-stage development of chronic Hepatitis B therapies.

Global Pharma | 01/01/2025 | By Manvi |  427

ADC Therapeutics Completes Phase 3 Enrollment in LOTIS-5 Trial

ADC Therapeutics SA has completed enrollment in the Phase 3 LOTIS-5 trial, evaluating ZYNLONTA (loncastuximab tesirine-lpyl) with rituximab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

Global Pharma | 31/12/2024 | By Manvi |  144

Duality Biologics Announces License Exercise by BeiGene for B7H4 ADC

Duality Biologics announced that BeiGene Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074, securing global rights for the development, manufacturing, and commercialisation of the investigational therapy.

Global Pharma | 31/12/2024 | By Manvi |  195

Immedica Announces Acquisition of Marinus Pharmaceuticals

The acquisition complements and further strengthens Immedica’s global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, approved by the U.S. Food and Drug Administration (FDA) in March 2022.

Global Pharma | 31/12/2024 | By Aishwarya |  402

Vincerx Pharma Signs Binding Term Sheet for a Strategic Merger with Oqory

Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work.

Global Pharma | 31/12/2024 | By Aishwarya |  397

Precigen Completes Submission for BLA to USFDA for PRGN-2012

The submission is in the initial 60 day review period, during which time the FDA will decide whether to accept the BLA for further review and set the Prescription Drug User Fee Act (PDUFA) action date.

Global Pharma | 30/12/2024 | By Manvi |  398

USFDA Approves Bristol Myers Squibb's 'Opdivo Qvantig Injection'

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase (rHuPH20).

Global Pharma | 30/12/2024 | By Manvi |  198

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849

IDEAYA Biosciences has secured an exclusive global license (outside China) from Jiangsu Hengrui Pharmaceuticals for SHR-4849, a novel DLL3-targeting ADC program with promising early clinical results in solid tumours, including small cell lung cancer.

Global Pharma | 30/12/2024 | By Manvi |  186